Immunomodulatory effects of probiotic bacteria DNA: IL-1 and IL-10 response in human peripheral blood mononuclear cells

被引:214
作者
Lammers, KM
Brigidi, P
Vitali, B
Gionchetti, P
Rizzello, F
Caramelli, E
Matteuzzi, D
Campieri, M
机构
[1] Univ Bologna, Policlin S Orsola, Dept Internal Med & Gastroenterol, I-40138 Bologna, Italy
[2] Univ Bologna, Dept Pharmaceut Sci, I-40126 Bologna, Italy
[3] Univ Bologna, Dept Histol & Gen Embryol, Bologna, Italy
来源
FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY | 2003年 / 38卷 / 02期
关键词
Bifidobacterium; Lactobacillus; bacterial DNA; inflammatory bowel disease; immune modulation;
D O I
10.1016/S0928-8244(03)00144-5
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A new therapeutic approach for inflammatory bowel diseases is based on the administration of probiotic bacteria. Prokaryotic DNA contains unmethylated CpG motifs which can activate immune responses, but it is unknown whether bacterial DNA is involved in the beneficial effects obtained by probiotic treatment. Peripheral blood mononuclear cells (PBMC) from healthy donors were incubated with pure DNA of eight probiotic strains and with total bacterial DNA from human feces collected before and after probiotic ingestion. Cytokine production was analyzed in culture supernatants. Modification of human microflora after probiotic administration was proven by polymerase chain reaction analysis. Here we show that Bifidobacterium genomic DNA induced secretion of the antiinflammatory interleukin-10 by PBMC. Total bacterial DNA from feces collected after probiotic administration modulated the immune response by a decrease of interleukin-1beta and an increase of interleukin-10. (C) 2003 Federation of European Microbiological Societies. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:165 / 172
页数:8
相关论文
共 23 条
[1]   Medicinal chemistry and therapeutic potential of CpG DNA [J].
Agrawal, S ;
Kandimalla, ER .
TRENDS IN MOLECULAR MEDICINE, 2002, 8 (03) :114-121
[2]  
Alander M, 1999, APPL ENVIRON MICROB, V65, P351
[3]   Specific detection of Bifidobacterium strains in a pharmaceutical probiotic product and in human feces by polymerase chain reaction [J].
Brigidi, P ;
Vitali, B ;
Swennen, E ;
Altomare, L ;
Rossi, M ;
Matteuzzi, D .
SYSTEMATIC AND APPLIED MICROBIOLOGY, 2000, 23 (03) :391-399
[4]   Probiotics in inflammatory bowel disease: New insight to pathogenesis or a possible therapeutic alternative? [J].
Campieri, M ;
Gionchetti, P .
GASTROENTEROLOGY, 1999, 116 (05) :1246-1249
[5]   Evaluation of media for selective enumeration of Streptococcus thermophilus, Lactobacillus delbrueckii ssp bulgaricus, Lactobacillus acidophilus, and bifidobacteria [J].
Dave, RI ;
Shah, NP .
JOURNAL OF DAIRY SCIENCE, 1996, 79 (09) :1529-1536
[6]  
Duchmann R, 1995, CLIN EXP IMMUNOL, V102, P448
[7]   Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials [J].
Dunne, C ;
Murphy, L ;
Flynn, S ;
O'Mahony, L ;
O'Halloran, S ;
Feeney, M ;
Morrissey, D ;
Thornton, G ;
Fitzgerald, G ;
Daly, C ;
Kiely, B ;
Quigley, EMM ;
O'Sullivan, GC ;
Shanahan, F ;
Collins, JK .
ANTONIE VAN LEEUWENHOEK INTERNATIONAL JOURNAL OF GENERAL AND MOLECULAR MICROBIOLOGY, 1999, 76 (1-4) :279-292
[8]  
Gilkeson GS, 1998, J IMMUNOL, V161, P3890
[9]   Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial [J].
Gionchetti, P ;
Rizzello, F ;
Venturi, A ;
Brigidi, P ;
Matteuzzi, D ;
Bazzocchi, G ;
Poggioli, G ;
Miglioli, M ;
Campieri, M .
GASTROENTEROLOGY, 2000, 119 (02) :305-309
[10]   Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial [J].
Gionchetti, P ;
Rizzello, F ;
Helwig, U ;
Venturi, A ;
Lammers, KM ;
Brigidi, P ;
Vitali, B ;
Poggioli, G ;
Miglioli, M ;
Campieri, M .
GASTROENTEROLOGY, 2003, 124 (05) :1202-1209